Patents by Inventor Jonathan Z. Long

Jonathan Z. Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical uncouplers of respiration and methods of use thereof
    Patent number: 11365177
    Abstract: Uncoupling of respiration is a well-recognized process that increases respiration and heat production in cells. Provided herein are chemical uncouplers of respiration that are compounds of Formula (I). Also provided are methods for preventing or treating metabolic disorders and modulating metabolic processes using compound of Formula (I).
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 21, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., University of Florida Research Foundation, Incorporated
    Inventors: Bruce M. Spiegelman, Jonathan Z. Long, Hua Lin, Theodore Kamenecka, Patrick Griffin
  • METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS
    Publication number: 20210106661
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using PM20D1 and N-lipidated amino acids.
    Type: Application
    Filed: October 28, 2016
    Publication date: April 15, 2021
    Inventors: Bruce M. Spiegelman, Jonathan Z. Long
  • CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF
    Publication number: 20200317613
    Abstract: Uncoupling of respiration is a well-recognized process that increases respiration and heat production in cells. Provided herein are chemical uncouplers of respiration that are compounds of Formula (I). Also provided are methods for preventing or treating metabolic disorders and modulating metabolic processes using compound of Formula (I).
    Type: Application
    Filed: November 29, 2018
    Publication date: October 8, 2020
    Inventors: Bruce M. Spiegelman, Jonathan Z Long, Hua Lin, Theodore Kamenecka, Patrick Griffin
  • Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
    Patent number: 10717992
    Abstract: The invention provides compositions and methods for regulating thermogenesis and muscle inflammation through modulation of Metrnl and/or Metrn activity and/or expression. Also provided are methods for preventing or treating metabolic disorders and muscle inflammation disorders in a subject through modulation of Metrnl and/or Metrn activity and/or expression. Further provided are methods for identifying compounds that are capable of treating metabolic disorders and muscle inflammation disorders by modulating Metrnl and/or Metrn activity and/or expression.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 21, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Rajesh R. Rao, Jonathan Z. Long
  • COMPOSITIONS AND METHODS FOR REGULATING THERMOGENESIS AND MUSCLE INFLAMMATION USING METRNL AND METRN
    Publication number: 20150322460
    Abstract: The invention provides compositions and methods for regulating thermogenesis and muscle inflammation through modulation of Metrnl and/or Metrn activity and/or expression. Also provided are methods for preventing or treating metabolic disorders and muscle inflammation disorders in a subject through modulation of Metrnl and/or Metrn activity and/or expression. Further provided are methods for identifying compounds that are capable of treating metabolic disorders and muscle inflammation disorders by modulating Metrnl and/or Metrn activity and/or expression.
    Type: Application
    Filed: January 21, 2014
    Publication date: November 12, 2015
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Bruce M. Spiegelman, Rajesh R. Rao, Jonathan Z. Long
  • Methods and compositions related to targeting monoacylglycerol lipase
    Patent number: 8772318
    Abstract: This invention provides compounds that selectively inhibit monoacylglycerol lipase (MAGL). The invention also provides methods of using the MAGL selective inhibitors to stimulate 2-Arachidonoylglycerol (2-AG) mediated endocannabinoid signaling in vivo, and to treat conditions that are associated with or linked to endocannabinoid signaling. The invention additionally provides methods of treating cancer or inhibiting tumor growth by targeting MAGL with MAGL specific inhibitors. The invention further provides methods of screening for MAGL inhibitors with improved biochemical and pharmaceutical properties.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: July 8, 2014
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Jonathan Z. Long, Weiwei Li, Daniel K. Nomura
  • METHODS AND COMPOSITIONS RELATED TO TARGETING MONOACYLGLYCEROL LIPASE
    Publication number: 20110275650
    Abstract: This invention provides compounds that selectively inhibit monoacylglycerol lipase (MAGL). The invention also provides methods of using the MAGL selective inhibitors to stimulate 2-Arachidonoylglycerol (2-AG) mediated endocannabinoid signaling in vivo, and to treat conditions that are associated with or linked to endocannabinoid signaling. The invention additionally provides methods of treating cancer or inhibiting tumor growth by targeting MAGL with MAGL specific inhibitors. The invention further provides methods of screening for MAGL inhibitors with improved biochemical and pharmaceutical properties.
    Type: Application
    Filed: November 10, 2009
    Publication date: November 10, 2011
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Jonathan Z. Long, Weiwei Li, Daniel K. Nomura